13.04
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ARQT Giù?
Forum
Previsione
Precedente Chiudi:
$13.67
Aprire:
$13.55
Volume 24 ore:
3.03M
Relative Volume:
1.30
Capitalizzazione di mercato:
$1.55B
Reddito:
$59.61M
Utile/perdita netta:
$-262.14M
Rapporto P/E:
-3.3265
EPS:
-3.92
Flusso di cassa netto:
$-247.49M
1 W Prestazione:
-6.72%
1M Prestazione:
-11.59%
6M Prestazione:
+0.00%
1 anno Prestazione:
+50.58%
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
Nome
Arcutis Biotherapeutics Inc
Settore
Industria
Telefono
805-418-5006
Indirizzo
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Confronta ARQT con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
ARQT
Arcutis Biotherapeutics Inc
|
13.04 | 1.67B | 59.61M | -262.14M | -247.49M | -3.92 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-12-30 | Iniziato | H.C. Wainwright | Buy |
2024-08-28 | Iniziato | Jefferies | Buy |
2024-01-03 | Aggiornamento | Mizuho | Neutral → Buy |
2023-10-26 | Downgrade | Mizuho | Buy → Neutral |
2023-10-13 | Downgrade | Goldman | Buy → Neutral |
2022-09-07 | Iniziato | Needham | Buy |
2022-03-17 | Iniziato | Goldman | Buy |
2021-06-30 | Iniziato | Mizuho | Buy |
2021-05-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
2020-11-09 | Aggiornamento | Goldman | Neutral → Buy |
2020-10-08 | Iniziato | Truist | Buy |
2020-02-25 | Iniziato | Cantor Fitzgerald | Overweight |
2020-02-25 | Iniziato | Cowen | Outperform |
2020-02-25 | Iniziato | Goldman | Neutral |
2020-02-25 | Iniziato | Guggenheim | Buy |
Mostra tutto
Arcutis Biotherapeutics Inc Borsa (ARQT) Ultime notizie
Possible Bearish Signals With Arcutis Biotherapeutics Insiders Disposing Stock - simplywall.st
Arcutis Biotherapeutics SVP sells $24,806 in stock By Investing.com - Investing.com South Africa
Arcutis Biotherapeutics SVP sells $24,806 in stock - Investing.com Australia
Arcutis to Present at the Goldman Sachs 46th Annual Global Healthcare Conference - The Manila Times
Immuno-Dermatology Leader Arcutis Set for Key Goldman Sachs Healthcare Conference Presentation - Stock Titan
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Shares Sold by Bank of America Corp DE - Defense World
Needham & Company LLC Reaffirms Buy Rating for Arcutis Biotherapeutics (NASDAQ:ARQT) - Defense World
Arcutis wins FDA nod for Zoryve foam for plaque psoriasis - MSN
Analyst Expectations For Arcutis Biotherapeutics's Future - Benzinga
ARQT Analyst Reiterates Buy Rating with $20 Price Target | ARQT Stock News - GuruFocus
Arcutis’ ZORYVE® (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older - BioSpace
FDA approves roflumilast foam 0.3% for scalp, body psoriasis - Contemporary Pediatrics
FDA approves ZORYVE foam for plaque psoriasis treatment - Investing.com Australia
FDA Approves Arcutis' (ARQT) Zoryve Foam for Psoriasis Treatment - GuruFocus
Arcutis Biotherapeutics' Foam Psoriasis Treatment Gets FDA Approval - marketscreener.com
FDA Approval Boosts Arcutis Biotherapeutics (ARQT) with New Psor - GuruFocus
Arcutis wins FDA nod for Zoryve foam in psoriasis (ARQT:NASDAQ) - Seeking Alpha
Arcutis' ZORYVE® (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older | ARQT Stock News - GuruFocus
FDA approves ZORYVE foam for plaque psoriasis treatment By Investing.com - Investing.com India
Understanding Roflumilast Foam's FDA Approval for Scalp and Body Psoriasis, with Jennifer Soung, MD - HCPLive
Arcutis' ZORYVE® (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older - The Manila Times
Better Weight Loss Stock: Amgen or Viking Therapeutics? - The Globe and Mail
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
79,815 Shares in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Acquired by BNP Paribas Financial Markets - Defense World
The Manufacturers Life Insurance Company Sells 1,547 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - Defense World
When the Price of (ARQT) Talks, People Listen - news.stocktradersdaily.com
ARQT: Key Insights from Genital Psoriasis Consensus Statements | - GuruFocus
New Consensus Statements on Impact of Genital Psoriasis on Patie - GuruFocus
Northern Trust Corp Acquires 54,541 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - Defense World
New Consensus Statements on Impact of Genital Psoriasis on Patients from Genital Psoriasis Wellness Consortium Published in Journal of the European Academy of Dermatology and Venereology Clinical Practice - The Manila Times
Arcutis Biotherapeutics Publishes Expert Consensus on Genital Psoriasis to Enhance Patient Care and Treatment Decision-Making - Nasdaq
Medical Breakthrough: Experts Release 14 Game-Changing Guidelines for Genital Psoriasis Treatment - Stock Titan
Chronic Hand Eczema Pipeline 2025: FDA Updates, Therapy - openPR.com
Chronic Hand Eczema Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Incyte Corp, LEO Pharma, Asana BioSciences, Arcutis Biotherapeutics - Barchart.com
Director’s Bold Move: A Major Investment in Arcutis Biotherapeutics - TipRanks
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Shares Sold by Price T Rowe Associates Inc. MD - Defense World
Hsbc Holdings PLC Increases Position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - Defense World
Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT) and AMN Healthcare Services (AMN) - The Globe and Mail
Arcutis outlines growth potential with ZORYVE expansions and market penetration - MSN
Earnings Update: Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts - simplywall.st
What is HC Wainwright’s Forecast for ARQT Q1 Earnings? - Defense World
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Tops Revenue Estimates - MSN
Arcutis Biotherapeutics: Zoryve foam treatment resulted in major improvements - Yahoo Finance
Arcutis Biotherapeutics First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q1 2025 Earnings Call Transcript - Insider Monkey
Arcutis Biotherapeutics Reports Strong Q1 Earnings Growth - TipRanks
Jefferies lifts Arcutis stock target to $20 on strong sales By Investing.com - Investing.com South Africa
ZORYVE foam shows promise in psoriasis treatment By Investing.com - Investing.com South Africa
ZORYVE foam shows promise in psoriasis treatment - Investing.com
Arcutis Announces Publication of Positive Data from ARRECTOR Tri - GuruFocus
Arcutis Biotherapeutics Inc Azioni (ARQT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):